Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution
Grace Hwang(University of Houston), Meghana V. Trivedi(University of Houston), Rutugandha Paranjpe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kelvin Lu(Methodist Hospital), Hanna Zaghloul(Houston Methodist), Uzoamaka Abajue(Methodist Hospital), Susan Abughosh(University of Houston), Carine Opsomer(Methodist Hospital)
Cited by 17
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133